X4 Pharmaceuticals (NASDAQ:XFOR) Price Target Cut to $4.00 by Analysts at Stifel Nicolaus

X4 Pharmaceuticals (NASDAQ:XFOR) had its price objective trimmed by Stifel Nicolaus from $5.00 to $4.00 in a research report released on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

X4 Pharmaceuticals Stock Down 1.8 %

NASDAQ XFOR traded down $0.01 during mid-day trading on Thursday, reaching $0.40. 2,436,015 shares of the company’s stock traded hands, compared to its average volume of 2,343,817. The company has a current ratio of 6.07, a quick ratio of 6.04 and a debt-to-equity ratio of 0.79. The company has a fifty day simple moving average of $0.59 and a 200-day simple moving average of $0.75. X4 Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $1.60. The company has a market cap of $67.87 million, a price-to-earnings ratio of -4.42 and a beta of 0.39.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Wednesday, August 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $3.43 million during the quarter. As a group, equities research analysts expect that X4 Pharmaceuticals will post -0.65 EPS for the current year.

Insider Buying and Selling at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 230,645 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $126,854.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Paula Ragan sold 239,436 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.55, for a total transaction of $131,689.80. Following the transaction, the chief executive officer now owns 1,057,713 shares of the company’s stock, valued at approximately $581,742.15. This represents a 18.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 580,800 shares of company stock valued at $321,447 in the last quarter. Corporate insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in XFOR. Price T Rowe Associates Inc. MD boosted its holdings in X4 Pharmaceuticals by 46.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock worth $55,000 after buying an additional 12,514 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of X4 Pharmaceuticals by 39.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock valued at $272,000 after purchasing an additional 133,398 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of X4 Pharmaceuticals by 14.6% during the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after purchasing an additional 23,831 shares in the last quarter. XTX Topco Ltd bought a new stake in X4 Pharmaceuticals during the second quarter worth about $65,000. Finally, Ensign Peak Advisors Inc raised its holdings in shares of X4 Pharmaceuticals by 4.6% during the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after purchasing an additional 111,032 shares during the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.